SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3) (1). SU14813 was developed as a next-generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity equivalent to that of sunitinib, which resulted in tumor regression, growth arrest, growth delay, and prolonged survival in established xenograft cancer models in mice.
MedKoo Cat#: 202710
Name: SU14813
CAS#: 627908-92-3 (free base)
Chemical Formula: C23H27FN4O4
Exact Mass: 442.2016
Molecular Weight: 442.48
Elemental Analysis: C, 62.43; H, 6.15; F, 4.29; N, 12.66; O, 14.46
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 54.0 | 122.04 | |
| DMF | 30.0 | 67.80 | |
| Ethanol | 0.1 | 0.23 | |
| PBS (pH 7.2) | 0.1 | 0.23 |
The following data is based on the product molecular weight 442.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
